Genetically Engineered Biomimetic ATP-Responsive Nanozyme for the Treatment of Cardiac Fibrosis

    January 2025 in “ Journal of Nanobiotechnology ”
    Xueli Zhao, Yuze Qin, Bowen Li … Yuanming Wu
    Studysummary This study demonstrated that genetically engineered, ATP-responsive nanozymes effectively reduce cardiac fibrosis by targeting activated cardiac fibroblasts, resulting in decreased myofibroblast accumulation and improved cardiac function, suggesting that this approach has significant potential for therapeutic applications.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jnanobiotechnology.biomedcentral.com →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Ceria Nanozyme-Integrated Microneedles Reshape the Perifollicular Microenvironment for Androgenetic Alopecia Treatment ACS Nano · 2021